Open Access

Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

  • Yi Fang Lee1,
  • Lance David Miller2,
  • Xiu Bin Chan1,
  • Michael A. Black6,
  • Brendan Pang3,
  • Chee Wee Ong3,
  • Manuel Salto-Tellez4, 5,
  • Edison T. Liu7 and
  • Kartiki V. Desai8Email author
Breast Cancer Research201719:42

DOI: 10.1186/s13058-017-0830-9

Received: 6 March 2017

Accepted: 6 March 2017

Published: 28 March 2017

The original article was published in Breast Cancer Research 2012 14:3001

Erratum

Main text: After the publication of this work [1] an error was noticed in Fig. 8. In the SMAD2P465/467 panel, the images for MCF-7 and MDA MB 231 cells were accidentally duplicated. The corrected figure is shown below. We apologize for this error, which does not affect the findings or conclusions of the article.
Fig. 8

JMJD6 expression affects SMAD phosphorylation. Immunoblots show that the level of total SMAD2/3, phosphorylated SMAD2 and phosphorylated SMAD3 are decreased in MCF-7 J1-OE clones, and increased in JMJD6 siRNA-mediated knock-down in MCF-7 and MDA-MB231. The numbers next to the SMAD2P/3P denote the expected sites of phosphorylation detected by the antibodies. N.S. denotes non-specific bands from the blots which indicate equal loading of the protein lysates

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Clearbridge BioMedics Private Ltd
(2)
Department of Cancer Biology, Wake Forest University School of Medicine
(3)
Department of Pathology, National University Health System and National University of Singapore
(4)
Centre for Cancer Research and Cell Biology, Queen’s University Belfast
(5)
Cancer Science Institute, National University of Singapore
(6)
Department of Biochemistry, Otago School of Medical Sciences, University of Otago
(7)
The Jackson Laboratory
(8)
National Institute of Biomedical Genomics, 2 Netaji Subash Sanatorium (T.B. Hospital)

Reference

  1. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast cancer research: BCR. 2012;14(3):R85.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement